A new computational model has allowed researchers to identify new therapeutic targets that can attack cancer cells by lowering their intracellular pH.
The study, which is the result of collaboration between IRB Barcelona, the Moffitt Cancer Center, and the University of Maryland, has been published in Nature Communications.
A team headed by Manuel Serrano at IRB Barcelona has designed a drug encapsulation system that selectively targets senescent cells.
The study paves the way for therapeutic approaches to eliminate senescent cells in many diseases, such as pulmonary fibrosis and cancer.
The scientist Roger Gomis receives funding from the “la Caixa” Foundation for a project devoted to metastatic breast cancer.
An international team led by computational biologist Fran Supek at IRB Barcelona develop a machine learning method to predict unknown gene functions of microbes.
The system examines and compares ‘big data’ available on the metagenomes of human and environmental microbiomes.
A new study by researchers at IRB Barcelona demonstrates that myeloid cells, which belong to the leucocyte family and form part of the innate immune system, use p38 protein signalling to support inflammation-associated colon cancer.
Published in EMBO Molecular Medicine, the study by Angel R. Nebreda suggests that inhibition of the p38 pathway in myeloid cells may be a useful therapeutic approach, especially in tumours associated with chronic inflammation.
Researchers at the Centre for Genomic Regulation (CRG) in collaboration with IRB Barcelona, developed a new method to systematically identify genes contributing to heritable cancer risk.
The study, published in Nature Communications, is a success story for data sharing and openness in science.
BIYSC 2018 starts with 90 students from all over the world.
IRB Barcelona receives today eight students that will participate through the workshop "Drosophila melanogaster: a model to study human disease".
A new study in collaboration with the Genomic Instability and Cancer Laboratory at IRB Barcelona and led by the University of Copenhagen, reveals that TLK2 displays lower levels of activity in intellectual disability and that it is possible to inhibit it in breast cancer, where it is overactive.
The study suggests that the enzyme may be a target for potential therapies.
Researchers at IRB Barcelona reveal that the protein NEK7 is relevant for the correct formation of neurons in the hippocampus, a region of the brain associated with memory.
Animals without NEK7 may also have defects in other other brain regions.